Amgen Inc



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.1%. By the end of trading, Amgen Inc rose 69 cents (1.3%) to $55.66 on average volume. Throughout the day, 9.5 million shares of Amgen Inc exchanged hands as compared to its average daily volume of 6.6 million shares. The stock ranged in a price between $54.63-$55.71 after having opened the day at $54.80 as compared to the previous trading day's close of $54.97. Other companies within the Drugs industry that increased today were:

Adeona Pharmaceuticals Inc



), up 19.1%,

ImmuCell Corporation



), up 16%,

Complete Genomics Inc



), up 14.2%, and

Cormedix Inc



), up 14%.

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Amgen Inc has a market cap of $48.71 billion and is part of the

health care

sector. The company has a P/E ratio of 13.8, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 0.1% year to date as of the close of trading on Monday.

TheStreet Ratings rates Amgen as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

Poniard Pharmaceuticals Inc



), down 25.4%,

Bionovo Inc



), down 15.7%,

Geron Corporation



), down 10.7%, and

YM Biosciences Inc



), down 9.4%, were all losers within the drugs industry with

Allergan Inc



) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech